Kaival Brands Innovations Group, Inc. (NASDAQ:
KAVL) ("Kaival Brands," the "Company" or "we,” “our” or
similar terms), the exclusive distributor of all products
manufactured by Bidi Vapor, LLC ("Bidi Vapor"), including the BIDI®
Stick electronic nicotine delivery system (ENDS), which are
intended for adults 21 and over, announced that management will be
presenting virtually at the H.C. Wainwright 25th Annual Global
Investment Conference.
As part of the presentation, Eric Mosser, CEO
and President of Kaival Brands, will discuss the Company’s product
offerings, products in development, regulatory initiatives and
efforts to drive revenue.
Interested parties may access the presentation
beginning on September 11 at 7:00 A.M. (ET) via
https://hcwevents.com/annualconference/.
Kaival Brands senior management will also be
available for virtual one-on-one meetings.
The Company’s PowerPoint presentation being
shown at the conference (as well as a replay of the Company’s
presentation itself) will be available at:
https://ir.kaivalbrands.com/events-and-presentations/default.aspx.
For additional information about the conference,
visit https://hcwevents.com/annualconference/
ABOUT KAIVAL BRANDS
Based in Grant-Valkaria, Florida, Kaival Brands
is a company focused on incubating innovative and profitable
adult-focused products into mature and dominant brands, with a
current focus on the distribution of electronic nicotine delivery
systems (ENDS) also known as “e-cigarettes”. Our business plan is
to seek to diversify into distributing other nicotine and
non-nicotine delivery system products (including those related to
hemp-derived cannabidiol (known as CBD) products). Kaival Brands
and Philip Morris Products S.A. (via sublicense from Kaival Brands)
are the exclusive global distributors of all products manufactured
by Bidi Vapor.
Learn more about Kaival Brands at
https://ir.kaivalbrands.com/overview/default.aspx.
ABOUT KAIVAL LABS
Based in Grant-Valkaria, Florida, Kaival Labs is
a 100% wholly-owned subsidiary of Kaival Brands focused on
developing new branded and white-label products and services in the
vaporizer and inhalation technology sectors. Kaival Labs’ current
patent portfolio consists of 12 existing and 46 pending with novel
technologies across extrusion dose control, product preservation,
tracking and tracing usage, multiple modalities and child safety.
The patents and patent applications cover territories including the
United States, Australia, Canada, China, the European Patent
Organisation, Israel, Japan, Mexico, New Zealand and South Korea.
The portfolio also includes a fully-functional proprietary mobile
device software application that is used in conjunction with
certain patents in the portfolio.
Learn more about Kaival Labs at
https://kaivallabs.com.
ABOUT BIDI VAPOR
Based in Melbourne, Florida, Bidi Vapor
maintains a commitment to responsible, adult-focused marketing,
supporting age-verification standards and sustainability through
its BIDI® Cares recycling program. Bidi Vapor's premier device, the
BIDI® Stick, is a premium product made with high-quality
components, a UL-certified battery and technology designed to
deliver a consistent vaping experience for adult smokers 21 and
over. Bidi Vapor is also adamant about strict compliance with all
federal, state and local guidelines and regulations. At Bidi Vapor,
innovation is key to its mission, with the BIDI® Stick promoting
environmental sustainability, while providing a unique vaping
experience to adult smokers.
Nirajkumar Patel, the Company’s Chief Science
and Regulatory Officer and director, owns and controls Bidi Vapor.
As a result, Bidi Vapor is considered a related party of the
Company.
For more information, visit
www.bidivapor.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release, the investor presentation
referred to herein and the statements of the Company’s management
and partners included herein, or made at such presentation, or
related to the subject matter hereof includes statements that
constitute “forward-looking statements” (as defined in Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended), which are statements
other than historical facts. You can identify forward-looking
statements by words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,”
“position,” “should,” “strategy,” “target,” “will,” and similar
words. All forward-looking statements speak only as of the date of
this press release. Although we believe that the plans, intentions,
and expectations reflected in or suggested by the forward-looking
statements are reasonable, there is no assurance that these plans,
intentions, or expectations will be achieved. Therefore, actual
outcomes and results (including, without limitation, the results of
the Company’s sales, marketing, development and regulatory
strategies) could materially and adversely differ from what is
expressed, implied, or forecasted in such statements. Our business
and results of operations may be influenced by many factors that
are difficult to predict, involve uncertainties that may materially
affect results, and are often beyond our control. Factors that
could cause or contribute to such differences include, but are not
limited to: (i) future actions by the FDA in response to the 11th
Circuit Court’s August 2022 decision that could impact our business
and prospects, (ii) the outcome of FDA’s scientific review of Bidi
Vapor’s pending FDA Premarket Tobacco Product Applications, (iii)
the results of international marketing and sales efforts by Philip
Morris International, the Company’s international distribution
partner, (iv) how quickly domestic and international markets adopt
our products, (v) the scope of future FDA enforcement of
regulations in the ENDS industry, (vi) the FDA’s approach to the
regulation of synthetic nicotine and its impact on our business,
(vii) potential federal and state flavor bans and other
restrictions on ENDS products, (viii) the duration and scope of the
COVID-19 pandemic and impact on the demand for the products we
distribute, (ix) general economic uncertainty in key global markets
and a worsening of global economic conditions or low levels of
economic growth, (x) the effects of steps that we may take to raise
new capital and reduce operating costs, (xi) our inability to
generate and sustain profitable sales growth, including sales
growth in U.S. and international markets, (xii) circumstances or
developments that may make us unable to implement or realize
anticipated benefits, or that may increase the costs, of our
current and planned business initiatives (including, without
limitation, the development of vaporization intellectual property
we acquired in late April 2023), (xiii) significant changes in our
relationships with our distributors or sub-distributors and (xiv)
other factors detailed by us in our public filings with the
Securities and Exchange Commission, including the disclosures under
the heading “Risk Factors” in our Annual Report on Form 10-K for
the fiscal year ended October 31, 2022, filed with the Securities
and Exchange Commission on January 27, 2023, as well as all of our
subsequent SEC filings, all of which are accessible
at www.sec.gov. All forward-looking statements included in
this press release are expressly qualified in their entirety by
such cautionary statements. Except as required under the federal
securities laws and the Securities and Exchange Commission’s rules
and regulations, we do not have any intention or obligation to
update any forward-looking statements publicly, whether as a result
of new information, future events, or otherwise.
Kaival Brands Investor Relations:Investor
Relations:Brett Maas, Managing PartnerHayden IR(646)
536-7331brett@haydenir.com
Kaival Brands Media & Press
Relations:Stephen Sheriff(646)
572-7086investors@kaivalbrands.com
Kaival Brands Innovations (NASDAQ:KAVL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Kaival Brands Innovations (NASDAQ:KAVL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024